Inoculating a global population once Covid-19 vaccines were available required the pharmaceutical industry to produce and mobilize an unprecedented number of doses. Success relied on global manufacturing capacity and rapid and efficient technology transfer, which disseminated the knowledge and ability to produce these vaccines.
This whitepaper provides an overview of the technology transfer process and describes how the development and optimization of a platform to manufacture a vaccine for tropical diseases that was subsequently leveraged for SARS-CoV-2 vaccine process development and transferred to Biofarma, a leading vaccine manufacturer in Indonesia.
